BR0114156A - Forma amorfa de inibidor de ciclo de célula - Google Patents

Forma amorfa de inibidor de ciclo de célula

Info

Publication number
BR0114156A
BR0114156A BR0114156-2A BRPI0114156A BR0114156A BR 0114156 A BR0114156 A BR 0114156A BR PI0114156 A BRPI0114156 A BR PI0114156A BR 0114156 A BR0114156 A BR 0114156A
Authority
BR
Brazil
Prior art keywords
cell cycle
amorphous form
cycle inhibitor
compound
inhibitor
Prior art date
Application number
BR0114156-2A
Other languages
English (en)
Inventor
Antonio A Albano
Wantanee Phuapradit
Harpreet K Sandhu
Navnit Hargovindas Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0114156A publication Critical patent/BR0114156A/pt
Publication of BRPI0114156B1 publication Critical patent/BRPI0114156B1/pt
Publication of BRPI0114156B8 publication Critical patent/BRPI0114156B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Extraction Or Liquid Replacement (AREA)

Abstract

"FORMA AMORFA DE INIBIDOR DE CICLO DE CéLULA". A presente invenção refere-se a uma forma farmaceuticamente ativa, amorfa de um composto de fórmula (I) que é substancialmente livre de composto cristalino.
BR0114156-2 2000-10-03 2001-09-26 processos para preparação de 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, em forma amorfa e composição farmacêutica BRPI0114156B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23756300P 2000-10-03 2000-10-03
PCT/EP2001/011119 WO2002028855A2 (en) 2000-10-03 2001-09-26 Amorphous form of cell cycle inhibitor

Publications (3)

Publication Number Publication Date
BR0114156A true BR0114156A (pt) 2003-07-29
BRPI0114156B1 BRPI0114156B1 (pt) 2018-09-11
BRPI0114156B8 BRPI0114156B8 (pt) 2021-05-25

Family

ID=22894259

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114156-2 BRPI0114156B8 (pt) 2000-10-03 2001-09-26 processos para preparação de 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, em forma amorfa e composição farmacêutica

Country Status (15)

Country Link
US (4) US6482847B2 (pt)
EP (1) EP1366040B1 (pt)
JP (3) JP2004510771A (pt)
KR (1) KR100554933B1 (pt)
CN (1) CN1250541C (pt)
AR (1) AR035064A1 (pt)
AT (1) ATE447566T1 (pt)
AU (2) AU1396502A (pt)
BR (1) BRPI0114156B8 (pt)
CA (1) CA2423286C (pt)
DE (1) DE60140382D1 (pt)
ES (1) ES2334012T3 (pt)
MX (1) MXPA03002858A (pt)
WO (1) WO2002028855A2 (pt)
ZA (1) ZA200301593B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
CA2471144C (en) * 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
US20100222311A1 (en) * 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds
US8268354B2 (en) * 2007-11-07 2012-09-18 Aridis Pharmaceuticals Sonic low pressure spray drying
WO2010132445A1 (en) * 2009-05-12 2010-11-18 Corcept Therapeutics, Inc. Solid forms and process for preparing
US8969588B2 (en) * 2012-06-05 2015-03-03 Gilead Pharmasset Llc Solid forms of an antiviral compound
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
US10369136B2 (en) * 2015-12-18 2019-08-06 Galecto Biotech Ab Polymorphic forms and process

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
JPH08208478A (ja) * 1994-10-14 1996-08-13 Japan Energy Corp 抗エイズ薬製剤およびその製造方法
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
TR200002580T2 (tr) 1998-03-17 2000-11-21 F.Hoffmann-La Roche Ag Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
US6036736A (en) 1998-04-03 2000-03-14 Wells Manufacturing Company, Inc. Ventilating method and apparatus
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
SE9803261D0 (sv) 1998-09-25 1998-09-25 Siemens Elema Ab Andningsapparat
CA2362016A1 (en) * 1999-03-03 2000-09-08 Kenneth Philip Moder Echinocandin/carbohydrate complexes
US6326501B1 (en) 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability

Also Published As

Publication number Publication date
ATE447566T1 (de) 2009-11-15
CA2423286A1 (en) 2002-04-11
US6486329B1 (en) 2002-11-26
AU1396502A (en) 2002-04-15
JP2008056670A (ja) 2008-03-13
US20020173533A1 (en) 2002-11-21
BRPI0114156B1 (pt) 2018-09-11
BRPI0114156B8 (pt) 2021-05-25
AR035064A1 (es) 2004-04-14
US20020173532A1 (en) 2002-11-21
CA2423286C (en) 2008-10-28
US6469180B1 (en) 2002-10-22
US6492530B1 (en) 2002-12-10
WO2002028855A3 (en) 2003-09-12
US6482847B2 (en) 2002-11-19
EP1366040A2 (en) 2003-12-03
KR20030036872A (ko) 2003-05-09
ZA200301593B (en) 2004-06-22
JP5341331B2 (ja) 2013-11-13
DE60140382D1 (de) 2009-12-17
US20020061922A1 (en) 2002-05-23
ES2334012T3 (es) 2010-03-04
WO2002028855A2 (en) 2002-04-11
CN1250541C (zh) 2006-04-12
JP2012136534A (ja) 2012-07-19
JP2004510771A (ja) 2004-04-08
CN1468231A (zh) 2004-01-14
US20020173534A1 (en) 2002-11-21
EP1366040B1 (en) 2009-11-04
AU2002213965B2 (en) 2007-07-19
KR100554933B1 (ko) 2006-03-03
MXPA03002858A (es) 2003-07-14

Similar Documents

Publication Publication Date Title
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
DK1485359T3 (da) Natriumkanalblokkere
EP1403255A4 (en) INHIBITORS OF RHO KINASE
BR0308979A (pt) Derivados de indolilmaleimida
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
BR0014075A (pt) Inibidores de quinase como agentes terapêuticos
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
BR0114156A (pt) Forma amorfa de inibidor de ciclo de célula
ATE297203T1 (de) Antithrombotische mitteln
RS26604A (en) Spiro-hydantoin compounds useful as anti-inflamatory agents
NO20030885D0 (no) Inhibitorer av <alfa>4 styrt celleadhesjon
EA200200819A1 (ru) Кристаллическая форма ii линезолида
EA200100301A2 (ru) НОВЫЙ СПОСОБ ПОЛУЧЕНИЯ 11-АМИНО-3-ХЛОР-6,11-ДИГИДРО-5,5-ДИОКСО-6-МЕТИЛДИБЕНЗО[c,f][1,2]ТИАЗЕПИНА И ЕГО ПРИМЕНЕНИЕ ДЛЯ СИНТЕЗА ТИАНЕПТИНА
IS5497A (is) Bífenýlamidínafleiður
HU0201083D0 (pt)
MY140666A (en) Biotinylated hexadecasaccharides, preparation and use thereof
DE60114640D1 (en) Antithrombosemittel
NO20022977D0 (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
CO5261576A1 (es) Compuestos
BR0208513A (pt) Processo de preparação de benazepril
EP1707560A4 (en) HYDROXAMIC ACID DERIVATIVE AND THE DERIVATIVE INHIBITOR OF THE GENERATION OF AGE
UY26778A1 (es) Derivados de ácido heteroarilalcanoico.
RS20050824A (en) Novel intermediate for the preparation of therapeutically active imidazopyridines
ECSP003854A (es) Procedimientos y compuestos para la inhibicion de la mrp 1
CO5540305A2 (es) Proceso para la produccion del derivado de piperidina fexofenadina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 26/09/2021